FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4223412810> ?p ?o ?g. }

• W4223412810 endingPage "2730" @default.
• W4223412810 startingPage "2717" @default.
• W4223412810 abstract "Hyperkalemia is associated with increased morbidity and mortality in patients with chronic kidney disease (CKD). Patiromer (Veltassa®) is an oral potassium binder indicated for the treatment of hyperkalemia in adults. We evaluated the impact of patiromer on the Swiss healthcare resources when used in patients with CKD and hyperkalemia who were on renin–angiotensin–aldosterone system inhibitor (RAASi) treatment. We built a decision tree and calculated the number needed to treat (NNT) to prevent hyperkalemia, hospitalization, and death based on published aggregated data. The decision tree was populated with available data from relevant patiromer clinical trials and data were applied to create a simple model showing the expected effectiveness of adding patiromer to the treatment of patients with medium-to-severe stage CKD on RAASi compared to RAASi only. Adapting the model to the Swiss healthcare system allowed us to estimate the impact of the new treatment on healthcare expenditures from a payer as well as a Swiss public healthcare perspective. Patiromer reduced the absolute risk for recurrent hyperkalemia by 48% within 8 weeks, resulting in an NNT of 2.1 [95% CI 1.4, 3.7]. If one assumes that 90%, 50%, or 10% of all moderate-to-severe hyperkalemic events lead to hospitalization, the NNT to prevent one hospitalization would be 2.5, 4.4, and 22.2, respectively. On the basis of the death rate of patients with mild or moderate-to-severe hyperkalemia, and the prevalence of mild or moderate-to-severe hyperkalemia in the treatment and control groups, the NNT was 78.7 [95% CI 64.0, 99.3] to prevent one death. Patiromer resulted in expected cost offsets of CHF 303 (1 CHF = 0.95 EUR as of 2022) per patient over 8 weeks in Switzerland. Patiromer used for the treatment of CKD reduces hyperkalemia recurrence leading to improved patient care. This results in substantial offset costs for the Swiss healthcare system." @default.
• W4223412810 created "2022-04-14" @default.
• W4223412810 creator A5053852502 @default.
• W4223412810 creator A5086779049 @default.
• W4223412810 creator A5090989641 @default.
• W4223412810 date "2022-04-13" @default.
• W4223412810 modified "2023-10-06" @default.
• W4223412810 title "Cost-Effectiveness of Treating Patients with Chronic Kidney Disease and Prior Hyperkalemia with Renin–Angiotensin–Aldosterone System Inhibitor and Patiromer: A Swiss Public Healthcare Perspective" @default.
• W4223412810 cites W1756552807 @default.
• W4223412810 cites W1969435326 @default.
• W4223412810 cites W1970939567 @default.
• W4223412810 cites W1978945831 @default.
• W4223412810 cites W2063686321 @default.
• W4223412810 cites W2063878239 @default.
• W4223412810 cites W2098356398 @default.
• W4223412810 cites W2119340816 @default.
• W4223412810 cites W2152271789 @default.
• W4223412810 cites W2182000067 @default.
• W4223412810 cites W2219432653 @default.
• W4223412810 cites W2324948948 @default.
• W4223412810 cites W2577614303 @default.
• W4223412810 cites W2770649031 @default.
• W4223412810 cites W2790169725 @default.
• W4223412810 cites W2806894205 @default.
• W4223412810 cites W2885035206 @default.
• W4223412810 cites W2920857322 @default.
• W4223412810 cites W2948407021 @default.
• W4223412810 cites W2972966903 @default.
• W4223412810 cites W2999898828 @default.
• W4223412810 cites W3003149826 @default.
• W4223412810 cites W2034290238 @default.
• W4223412810 doi "https://doi.org/10.1007/s12325-022-02123-3" @default.
• W4223412810 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35416597" @default.
• W4223412810 hasPublicationYear "2022" @default.
• W4223412810 type Work @default.
• W4223412810 citedByCount "1" @default.
• W4223412810 countsByYear W42234128102023 @default.
• W4223412810 crossrefType "journal-article" @default.
• W4223412810 hasAuthorship W4223412810A5053852502 @default.
• W4223412810 hasAuthorship W4223412810A5086779049 @default.
• W4223412810 hasAuthorship W4223412810A5090989641 @default.
• W4223412810 hasBestOaLocation W42234128101 @default.
• W4223412810 hasConcept C126322002 @default.
• W4223412810 hasConcept C177713679 @default.
• W4223412810 hasConcept C2778653478 @default.
• W4223412810 hasConcept C2780243291 @default.
• W4223412810 hasConcept C44249647 @default.
• W4223412810 hasConcept C67774102 @default.
• W4223412810 hasConcept C71924100 @default.
• W4223412810 hasConcept C82789193 @default.
• W4223412810 hasConceptScore W4223412810C126322002 @default.
• W4223412810 hasConceptScore W4223412810C177713679 @default.
• W4223412810 hasConceptScore W4223412810C2778653478 @default.
• W4223412810 hasConceptScore W4223412810C2780243291 @default.
• W4223412810 hasConceptScore W4223412810C44249647 @default.
• W4223412810 hasConceptScore W4223412810C67774102 @default.
• W4223412810 hasConceptScore W4223412810C71924100 @default.
• W4223412810 hasConceptScore W4223412810C82789193 @default.
• W4223412810 hasFunder F4320323906 @default.
• W4223412810 hasIssue "6" @default.
• W4223412810 hasLocation W42234128101 @default.
• W4223412810 hasLocation W42234128102 @default.
• W4223412810 hasLocation W42234128103 @default.
• W4223412810 hasOpenAccess W4223412810 @default.
• W4223412810 hasPrimaryLocation W42234128101 @default.
• W4223412810 hasRelatedWork W2063784476 @default.
• W4223412810 hasRelatedWork W2807375651 @default.
• W4223412810 hasRelatedWork W2938573757 @default.
• W4223412810 hasRelatedWork W2938706758 @default.
• W4223412810 hasRelatedWork W3167292191 @default.
• W4223412810 hasRelatedWork W3212622766 @default.
• W4223412810 hasRelatedWork W4200212049 @default.
• W4223412810 hasRelatedWork W4245370611 @default.
• W4223412810 hasRelatedWork W4320491482 @default.
• W4223412810 hasRelatedWork W4327895846 @default.
• W4223412810 hasVolume "39" @default.
• W4223412810 isParatext "false" @default.
• W4223412810 isRetracted "false" @default.
• W4223412810 workType "article" @default.